Amiksin tablets 125mg, No. 6

In adults

• for the prevention and treatment of influenza and ARVI;

• for the treatment of viral hepatitis A, B and C;

• for the treatment of herpes infection;

• for the treatment of cytomegalovirus infection;

• as part of the complex therapy of allergic and viral encephalomyelitis (including multiple sclerosis, leukoencephalitis, uveoencephalitis);

• as part of the complex therapy of urogenital and respiratory chlamydia;

• as part of the complex therapy of pulmonary tuberculosis.

  In children older

• 7 years for the treatment of influenza and SARS.

The drug is taken orally after meals.

In adults, for non-specific prophylaxis of viral hepatitis A, the drug is prescribed at a dose of 125 mg once a week for 6 weeks. Heading dose - 750 mg (6 tab.). In the treatment of viral hepatitis A, the dose of the drug on the first day is 125 mg 2 times / day, then they switch to 125 mg after 48 hours. The course of treatment is 1.25 g (10 tablets).

In the treatment of acute hepatitis B in the initial phase of treatment on the first and second days, the dose of the drug is 125 mg / day, and then 125 mg after 48 hours. The course of treatment is 2 g (16 tablets). With a prolonged course of hepatitis B on the first day, the dose of the drug is 125 mg 2 times / day, then 125 mg after 48 hours. The course dose is 2.5 g (20 tab.).

In chronic hepatitis B in the initial phase of treatment, the total dose is 2.5 g (20 tab.). In the first 2 days, the daily dose is 250 mg, then they switch to 125 mg after 48 hours.In the continuation phase of treatment, the total dose ranges from 1.25 g (10 tablets) to 2.5 g (20 tablets), while the drug is prescribed at a dose of 125 mg per week. The course dose of Amiksin varies from 3.75 to 5 g, the duration of treatment is 3.5-6 months, depending on the results of biochemical, immunological and morphological studies, reflecting the degree of activity of the process.

In acute hepatitis C on the first and second day of treatment, AmiksinЃ is prescribed at a dose of 125 mg / day, then 125 mg after 48 hours. The course dose is 2.5 g (20 tab.).

In chronic hepatitis C in the initial phase of treatment, the total dose is 2.5 g (20 tab.). In the first 2 days, the drug is taken at a dose of 250 mg / day, then 125 mg after 48 hours. In the continuation phase of treatment, the total dose is 2.5 g (20 tab.), While the drug is prescribed at a dose of 125 mg per week. The course dose of Amiksin is 5 g (40 tab.), The duration of treatment is 6 months, depending on the results of biochemical, immunological and morphological studies, reflecting the degree of activity of the process.

In the complex therapy of neuroviral infections - 125-250 mg / day in the first two days of treatment, then 125 mg after 48 hours. The dose is set individually, the duration of the course of treatment is 3-4 weeks. For the treatment of influenza and other acute respiratory viral infections in the first 2 days of illness, AmiksinЃ is prescribed at a dose of 125 mg / day, then 125 mg after 48 hours. The course dose is 750 mg (6 tab.).

For the prevention of influenza and ARVI, AmiksinЃ is prescribed at a dose of 125 mg once a week for 6 weeks. Heading dose - 750 mg (6 tab.). For the treatment of herpes, cytomegalovirus infection, the dose of the drug in the first 2 days is 125 mg, then 125 mg is taken after 48 hours. The course dose is 1.25-2.5 g (10-20 tab.).

In urogenital and respiratory chlamydia, AmiksinЃ is prescribed at a dose of 125 mg / day for the first 2 days, then 125 mg every 48 hours. The course dose is 1.25 g (10 tab.).

In the complex therapy of pulmonary tuberculosis in the first 2 days, the drug is prescribed at 250 mg / day, then at 125 mg every 48 hours. The course dose is 2.5 g (20 tab.). For children over 7 years old with uncomplicated forms of influenza or other acute respiratory viral infections, the drug is prescribed at a dose of 60 mg (1 tab.) 1 time / day after meals on the 1st, 2nd and 4th day from the start of treatment. Heading dose - 180 mg (3 tab.).

With the development of complications of influenza and other acute respiratory viral infections, the drug is taken at 60 mg 1 time / day on the 1st, 2nd, 4th, 6th day from the start of treatment. Heading dose - 240 mg (4 tab.).

Orange film-coated tablets, round, biconvex; on the break - orange, slight inclusions of orange or white are allowed.

1 tab.

tilorone (tilaxin) 125 mg

Excipients: potato starch, microcrystalline cellulose, povidone (Kollidon 30), calcium stearate, croscarmellose sodium (primellose).

• Pregnancy;

• breastfeeding period;

• children under 7 years of age;

• hypersensitivity to the drug.

pharmachologic effect

Low molecular weight synthetic interferon inducer that stimulates the formation of alpha, beta, gamma interferons in the body. The main structures producing interferon in response to the administration of tilorone are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After taking the drug inside, the maximum production of interferon is determined in the intestine-liver-blood sequence after 4-24 hours. AmiksinЃ has an immunomodulatory and antiviral effect. In human leukocytes, it induces the synthesis of interferon. Stimulates bone marrow stem cells, depending on the dose, increases antibody production, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers. Effective for various viral infections (including those caused by influenza viruses,other causative agents of acute respiratory viral infections, hepatitis viruses, herpes). The mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.

Pharmacokinetics

Suction

After taking the drug inside, tilorone is rapidly absorbed from the gastrointestinal tract. Bioavailability is about 60%.

Distribution

Plasma protein binding is about 80%.

Metabolism and excretion

Tilorone does not undergo biotransformation and does not accumulate in the body. It is excreted practically unchanged in the feces (about 70%) and urine (about 9%). T1 / 2 is 48 hours.

Side effect

From the digestive system: symptoms of dyspepsia are possible. Others: short-term chills, allergic reactions are possible.

Application during pregnancy and lactation

AmiksinЃ is contraindicated for use during pregnancy and during breastfeeding.

Application in children

Contraindication: children under 7 years of age.

special instructions

AmiksinЃ is compatible with antibiotics and traditional treatments for viral and bacterial infections.

Overdose

To date, cases of overdose of AmiksinЃ are unknown.

Drug interactions

No clinically significant drug interactions between Amiksin and antibiotics and traditional treatments for viral and bacterial infections have been identified.